Found: 31
Select item for more details and to access through your institution.
Sequencing of Targeted Therapy in Psoriasis: Does it Matter?
- Published in:
- American Journal of Clinical Dermatology, 2024, v. 25, n. 5, p. 795, doi. 10.1007/s40257-024-00874-z
- By:
- Publication type:
- Article
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2235, doi. 10.1007/s13555-024-01224-x
- By:
- Publication type:
- Article
Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2).
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 8, p. 1543, doi. 10.1111/jdv.19925
- By:
- Publication type:
- Article
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.
- Published in:
- British Journal of Dermatology, 2024, v. 190, n. 4, p. 477, doi. 10.1093/bjd/ljad429
- By:
- Publication type:
- Article
Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 12, p. 3031, doi. 10.1007/s13555-023-01054-3
- By:
- Publication type:
- Article
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 2, p. 495, doi. 10.1007/s13555-021-00649-y
- By:
- Publication type:
- Article
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 2, p. 561, doi. 10.1007/s13555-021-00679-6
- By:
- Publication type:
- Article
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study.
- Published in:
- American Journal of Clinical Dermatology, 2020, v. 21, n. 6, p. 881, doi. 10.1007/s40257-020-00555-7
- By:
- Publication type:
- Article
Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Comparative Effectiveness Studies for Psoriasis-The Methods Matter.
- Published in:
- 2020
- By:
- Publication type:
- editorial
Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Consistent responses with guselkumab treatment in Asian and non‐Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2.
- Published in:
- Journal of Dermatology, 2019, v. 46, n. 12, p. 1141, doi. 10.1111/1346-8138.15109
- By:
- Publication type:
- Article
Eruptive Xanthoma During Antiretroviral Therapy.
- Published in:
- Journal of Microbiology & Infectious Diseases, 2019, v. 9, n. 1, p. 43, doi. 10.5799/jmid.537168
- By:
- Publication type:
- Article
Core Outcome Sets for Psoriasis Clinical Trials: Definition, Consensus, and Acceptance.
- Published in:
- 2018
- By:
- Publication type:
- editorial
Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Patient Satisfaction and Quality of Life in Psoriasis and Psoriatic Arthritis.
- Published in:
- JAMA: Journal of the American Medical Association, 2014, v. 312, n. 24, p. 2676, doi. 10.1001/jama.2014.12494
- By:
- Publication type:
- Article
A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis.
- Published in:
- Journal of Investigative Dermatology, 2012, v. 132, n. 2, p. 304, doi. 10.1038/jid.2011.304
- By:
- Publication type:
- Article
Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events: A Meta-analysis of Randomized Controlled Trials.
- Published in:
- JAMA: Journal of the American Medical Association, 2011, v. 306, n. 8, p. 864, doi. 10.1001/jama.2011.1211
- By:
- Publication type:
- Article
Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
- Published in:
- Dermatologic Therapy, 2009, v. 22, n. 5, p. 431, doi. 10.1111/j.1529-8019.2009.01259.x
- By:
- Publication type:
- Article
Treatment Satisfaction and Health-related Quality of Life among Individuals with Psoriasis: National Psoriasis Foundation Survey Findings.
- Published in:
- Psoriasis Forum, 2008, n. 2, p. 27, doi. 10.1177/247553030814a00205
- By:
- Publication type:
- Article
Efficacy and Safety of Adalimumab Treatment in Patients with Moderate to Severe Psoriasis: A Double-Blind, Randomized Clinical Trial.
- Published in:
- Psoriasis Forum, 2007, n. 1, p. 4, doi. 10.1177/247553030713a00101
- By:
- Publication type:
- Article
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: A phase IIIb, randomized, controlled trial.
- Published in:
- 2006
- By:
- Publication type:
- Other
Clinical Efficacy of Efalizumab in Patients With Chronic Plaque Psoriasis: Results From Three Randomized Placebo-Controlled Phase III Trials: Part I.
- Published in:
- Journal of Cutaneous Medicine & Surgery, 2005, v. 9, n. 6, p. 303, doi. 10.1007/s10227-005-0116-1
- By:
- Publication type:
- Article
The Efficacy of Alefacept in the Treatment of Chronic Plaque Psoriasis.
- Published in:
- Journal of Cutaneous Medicine & Surgery, 2004, v. 8, p. 3, doi. 10.1007/s10227-004-9502-3
- By:
- Publication type:
- Article
Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis.
- Published in:
- Dermatologic Therapy, 2004, v. 17, n. 5, p. 427, doi. 10.1111/j.1396-0296.2004.04045.x
- By:
- Publication type:
- Article
The Efficacy of Alefacept in the Treatment of Chronic Plaque Psoriasis.
- Published in:
- Journal of Cutaneous Medicine & Surgery, 2004, v. 8, p. 3, doi. 10.1177/12034754040080S202
- By:
- Publication type:
- Article
Efalizumab for Patients With Moderate to Severe Plaque Psoriasis: A Randomized Controlled Trial.
- Published in:
- JAMA: Journal of the American Medical Association, 2003, v. 290, n. 23, p. 3073, doi. 10.1001/jama.290.23.3073
- By:
- Publication type:
- Article
Comparative tolerability of systemic treatments for plaque-type psoriasis.
- Published in:
- 2002
- By:
- Publication type:
- journal article
In Vivo Gene Therapy with Interleukin-12 Inhibits Primary Vascular Tumor Growth and Induces Apoptosis in a Mouse Model<sup>1</sup>.
- Published in:
- Journal of Investigative Dermatology, 1999, v. 112, n. 5, p. 775, doi. 10.1046/j.1523-1747.1999.00587.x
- By:
- Publication type:
- Article
Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy.
- Published in:
- 1995
- By:
- Publication type:
- journal article